Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chronic kidney disease

Treatment of hepatitis C virus infection in patients with CKD

Nature Reviews Nephrology volume 12, pages 5–6 (2016)Cite this article

Subjects

Treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) can be challenging. Now, data from the phase III C-SURFER study show that grazoprevir and elbasvir — a new all-oral combination therapy for HCV — is safe and effective in patients with stage 4–5 CKD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Li, P. K. & Chow, K. M. Infectious complications in dialysis — epidemiology and outcomes. Nat. Rev. Nephrol. 8, 77–88 (2011).

    Article  Google Scholar 

  2. Fabrizi, F. et al. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J. Viral Hepat. 21, 681–689 (2014).

    Article  CAS  Google Scholar 

  3. Roth, D. et al. Grazoprevir-elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 17–23 (2015).

    Article  Google Scholar 

  4. Webster, D. P. et al. Hepatitis C. Lancet 385, 1124–1135 (2015).

    Article  Google Scholar 

  5. Saxena, V. et al. SLP08: Safety and efficacy of Sofosbuvir-containing regimes in HCV infected patients with reduced renal function: real-world experience from HCV-TARGET. J. Hepatol. 62, S267 (2015).

    Article  Google Scholar 

  6. Ferenci, P. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370, 1983–1992 (2014).

    Article  Google Scholar 

  7. Pockros, P. et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabusvir for treatment HCV genotype 1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 Study. J. Hepatol. 62, S257 (2015).

    Article  Google Scholar 

  8. Zeuzem, S. et al. Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patient with chronic HCV genotype 1, 4 and 6 infection: a randomized trial. Ann. Intern. Med. 163, 1–13 (2015).

    Article  Google Scholar 

  9. Fabrizi, F. et al. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J. Viral Hepat. 19, 601–607 (2012).

    Article  CAS  Google Scholar 

  10. International Society of Nephrology. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. Suppl. 109, S1–S99 (2008).

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, 9/F Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, Hong Kong

    Henry Lik-Yuen Chan

  2. Department of Medicine and Therapeutics, Carol & Richard Yu PD Research Centre, The Chinese University of Hong Kong, 9/F Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, Hong Kong

    Philip Kam-Tao Li

Authors
  1. Henry Lik-Yuen Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip Kam-Tao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Kam-Tao Li.

Ethics declarations

Competing interests

H.L.-Y.C. is an advisor and speaker for Abbvie, Bristol Myers Squibb, Gilead, Novartis Pharmaceutical and Roche; an advisor for Janssen; a speaker for Echosens; and has received an unrestricted grant from Roche for studies of hepatitis B virus. P.K.-T.L. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, HY., Li, PT. Treatment of hepatitis C virus infection in patients with CKD. Nat Rev Nephrol 12, 5–6 (2016). https://doi.org/10.1038/nrneph.2015.189

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2015.189

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing